JP2022538898A5 - - Google Patents
Info
- Publication number
- JP2022538898A5 JP2022538898A5 JP2021578078A JP2021578078A JP2022538898A5 JP 2022538898 A5 JP2022538898 A5 JP 2022538898A5 JP 2021578078 A JP2021578078 A JP 2021578078A JP 2021578078 A JP2021578078 A JP 2021578078A JP 2022538898 A5 JP2022538898 A5 JP 2022538898A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- less
- dosage
- oatp
- reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869389P | 2019-07-01 | 2019-07-01 | |
| US62/869,389 | 2019-07-01 | ||
| PCT/US2020/040515 WO2021003279A1 (en) | 2019-07-01 | 2020-07-01 | System for enhancing therapeutic compliance of the anti-cancer compound e7766 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538898A JP2022538898A (ja) | 2022-09-06 |
| JP2022538898A5 true JP2022538898A5 (https=) | 2023-07-11 |
| JP7704690B2 JP7704690B2 (ja) | 2025-07-08 |
Family
ID=71895194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578078A Active JP7704690B2 (ja) | 2019-07-01 | 2020-07-01 | 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12564600B2 (https=) |
| EP (1) | EP3993809B1 (https=) |
| JP (1) | JP7704690B2 (https=) |
| KR (1) | KR20220029717A (https=) |
| CN (1) | CN114599374A (https=) |
| AU (1) | AU2020300543A1 (https=) |
| BR (1) | BR112021026876A2 (https=) |
| CA (1) | CA3145824A1 (https=) |
| MX (1) | MX2022000052A (https=) |
| WO (1) | WO2021003279A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024533394A (ja) | 2021-09-09 | 2024-09-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｓｔｉｎｇアゴニストのバイオマーカー及びその使用方法 |
| CN115512788B (zh) * | 2022-09-16 | 2023-08-08 | 山东大学 | 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2446893A1 (en) * | 2010-11-01 | 2012-05-02 | Bergen Teknologioverføring AS | Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters |
| JP2015516423A (ja) | 2012-05-07 | 2015-06-11 | ノバルティス アーゲー | アリスポリビルによる薬物動態の調節 |
| PL3265565T3 (pl) | 2015-03-04 | 2021-01-25 | Board Of Regents, The University Of Texas System | Sposoby leczenia nowotworu z hemizygotyczną utratą tp53 |
| JP2019512233A (ja) | 2016-03-10 | 2019-05-16 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 |
| US20200055883A1 (en) * | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| KR102512494B1 (ko) | 2017-06-30 | 2023-03-22 | 교와 가부시키가이샤 | 의약 |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
-
2020
- 2020-07-01 MX MX2022000052A patent/MX2022000052A/es unknown
- 2020-07-01 JP JP2021578078A patent/JP7704690B2/ja active Active
- 2020-07-01 KR KR1020227003441A patent/KR20220029717A/ko active Pending
- 2020-07-01 US US17/597,199 patent/US12564600B2/en active Active
- 2020-07-01 CA CA3145824A patent/CA3145824A1/en active Pending
- 2020-07-01 CN CN202080061033.0A patent/CN114599374A/zh active Pending
- 2020-07-01 EP EP20750022.4A patent/EP3993809B1/en active Active
- 2020-07-01 BR BR112021026876A patent/BR112021026876A2/pt unknown
- 2020-07-01 WO PCT/US2020/040515 patent/WO2021003279A1/en not_active Ceased
- 2020-07-01 AU AU2020300543A patent/AU2020300543A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sosnik et al. | New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery | |
| McLaughlin et al. | Dolutegravir-induced hyperglycaemia in a patient living with HIV | |
| Fazil et al. | Bisphosphonates: therapeutics potential and recent advances in drug delivery | |
| TWI533866B (zh) | 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途 | |
| EP4322942B1 (en) | Combination comprising everolimus and amcenestrant | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| TW200916103A (en) | Therapeutic compositions and methods | |
| US20180117042A1 (en) | Methods for treating respiratory syncytial virus infection | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| CN105579018A (zh) | 预制备用于治疗用途的药物的方法 | |
| RU2494736C2 (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| JP2022538898A5 (https=) | ||
| CN103327975A (zh) | 用于治疗多形性成胶质母细胞瘤的含有马西替坦的组合物 | |
| JP2023548429A5 (https=) | ||
| US20170209458A9 (en) | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias | |
| JP2025517509A5 (https=) | ||
| KR102512494B1 (ko) | 의약 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| IL173847A (en) | Pharmaceutical composition in a form of anhydrous self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs | |
| EP3937928A1 (en) | Capsid assembly modulator solid formulation | |
| Sims-McCallum | Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. | |
| RU2022101963A (ru) | Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766 | |
| Chang | Baloxavir Marboxil (Xofluza) |